Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 116

Results For "IRA"

1455 News Found

PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy
Biotech | February 17, 2022

PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy


USFDA approves Lupin’s Supplemental New Drug Application for Solosec
Drug Approval | February 17, 2022

USFDA approves Lupin’s Supplemental New Drug Application for Solosec

The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV


EMA approves Pfizer’s 20-valent pneumococcal conjugate vaccine
Biotech | February 16, 2022

EMA approves Pfizer’s 20-valent pneumococcal conjugate vaccine

Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia


Proactive For Her raises US $ 5.5 million in Series A Round
Startup | February 16, 2022

Proactive For Her raises US $ 5.5 million in Series A Round

The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru


Mankind Pharma acquires two brands from Dr Reddy’s
News | February 16, 2022

Mankind Pharma acquires two brands from Dr Reddy’s

The entire integration and transition of the brands is expected to be completed by March 2022


BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies
interviews | February 15, 2022

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post


Lilly's bebtelovimab receives EUA to treat mild-to-moderate Covid-19
Drug Approval | February 14, 2022

Lilly's bebtelovimab receives EUA to treat mild-to-moderate Covid-19

Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data


Clinical trials demonstrated safety of AstraZeneca and Sputnik Light vaccines combination
News | February 14, 2022

Clinical trials demonstrated safety of AstraZeneca and Sputnik Light vaccines combination

Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered


Glenmark to commercialize AstraZeneca’s asthma drug in Columbia
Biotech | February 14, 2022

Glenmark to commercialize AstraZeneca’s asthma drug in Columbia

AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia


Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct
News | February 14, 2022

Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct

Key takeaways of recent quarter & conference call highlights